Pliant Therapeutics Provides Update on BEACON-IPF
27 Jun 2025 //
GLOBENEWSWIRE
Pliant Therapeutics Presents Data at ATS International Conference
21 May 2025 //
GLOBENEWSWIRE
Pliant Therapeutics Updates on Q1 2025 Financial Results
08 May 2025 //
GLOBENEWSWIRE
Pliant Therapeutics Announces Strategic Workforce Realignment
01 May 2025 //
GLOBENEWSWIRE
Pliant Therapeutics Announces Ph 1 Data for PLN-101095 in Patient
17 Mar 2025 //
GLOBENEWSWIRE
Pliant Therapeutics Adopts Stockholder Rights Agreement
13 Mar 2025 //
GLOBENEWSWIRE
Pliant Updates Ph2b/3 Trial In Idiopathic Pulmonary Fibrosis
03 Mar 2025 //
GLOBENEWSWIRE
Pliant Updates BEACON-IPF Phase 2b/3 Trial In IPF Patients
07 Feb 2025 //
GLOBENEWSWIRE
Pliant Therapeutics Appoints Delphine as Chief Technical Officer
22 Jan 2025 //
GLOBENEWSWIRE
Pliant Announces Inducement Grant Under Nasdaq LR 5635(c)(4)
22 Jan 2025 //
GLOBENEWSWIRE
Pliant to Participate in 43rd Annual J.P. Morgan Conference
02 Jan 2025 //
GLOBENEWSWIRE
Pliant Therapeutics to Attend Stifel Healthcare Conference
06 Nov 2024 //
GLOBENEWSWIRE
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Rule
30 Sep 2024 //
GLOBENEWSWIRE
Aligos Appoints Hardean Achneck as Chief Medical Officer
24 Sep 2024 //
GLOBENEWSWIRE
Pliant Therapeutics To Attend Canaccord Genuity Growth Conference
06 Aug 2024 //
GLOBENEWSWIRE
Pliant Reports Positive Long-Term Data From INTEGRIS-PSC Phase 2a Trial
15 Jul 2024 //
GLOBENEWSWIRE
Pliant Therapeutics Appoints Steve Krognes To Board
13 Jun 2024 //
GLOBENEWSWIRE
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Rules
12 Jun 2024 //
GLOBENEWSWIRE
Pliant Presents Data From Bexotegrast Program At EASL International Congress
06 Jun 2024 //
GLOBENEWSWIRE
Pliant Presents Bexotegrast Data At American Thoracic Society Conference
21 May 2024 //
GLOBENEWSWIRE
Pliant Announces Positive Phase 2a Bexotegrast IPF Imaging Data
14 May 2024 //
GLOBENEWSWIRE
Pliant touts Ph 2a data for oral IPF drug that’s already in a pivotal study
14 May 2024 //
ENDPTS
Pliant Therapeutics To Present At EASL International Liver Congress
07 May 2024 //
GLOBENEWSWIRE
Pliant Provides Corporate Update, Q1 2024 Financial Results
06 May 2024 //
GLOBENEWSWIRE
Pliant Therapeutics to Participate in Upcoming Investor Events
01 May 2024 //
GLOBENEWSWIRE
Pliant Therapeutics to Participate in Upcoming Investor Events
02 Apr 2024 //
GLOBENEWSWIRE
Pliant Announces Upcoming Presentations at the 2024 American Thoracic Society
27 Mar 2024 //
GLOBENEWSWIRE
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan
12 Mar 2024 //
GLOBENEWSWIRE
Pliant Therapeutics Reports Fourth Quarter 2023 Financial Results
27 Feb 2024 //
GLOBENEWSWIRE
Pliant Therapeutics to Participate in Upcoming Investor Conferences
26 Feb 2024 //
GLOBENEWSWIRE
Pliant Therapeutics to Participate in Upcoming Investor Events
07 Feb 2024 //
GLOBENEWSWIRE
Pliant Therapeutics Announces Positive Safety Data from Phase 2a of Bexotegrast
04 Feb 2024 //
GLOBENEWSWIRE
Pliant to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
03 Jan 2024 //
GLOBENEWSWIRE
Pliant Therapeutics Presentations at Liver Meeting 2023 Highlight Bexotegrast
13 Nov 2023 //
GLOBENEWSWIRE
Pliant Therapeutics Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
Pliant Therapeutics to Participate in Upcoming Investor Conferences
08 Nov 2023 //
GLOBENEWSWIRE
Pliant Therapeutics Presentations at the Annual Meeting of the Society
06 Nov 2023 //
GLOBENEWSWIRE
Pliant Therapeutics Announces Three Presentations at the Annual Meeting
31 Oct 2023 //
GLOBENEWSWIRE
Pliant Therapeutics Phase 2a Data Evaluating Bexotegrast to be Highlighted
19 Oct 2023 //
GLOBENEWSWIRE
Pliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer
16 Oct 2023 //
GLOBENEWSWIRE
Pliant Announces Safety Data from Phase 2a Trial of Bexotegrast
26 Sep 2023 //
GLOBENEWSWIRE
Pliant`s stock up on early evidence of liver disease efficacy
26 Sep 2023 //
FIERCE BIOTECH
Pliant Therapeutics to Host Call to Discuss Interim Results from INTEGRIS-PSC
25 Sep 2023 //
GLOBENEWSWIRE
Pliant Therapeutics Appoints Minnie Kuo as Chief Development Officer
15 Sep 2023 //
GLOBENEWSWIRE
Pliant Therapeutics Announces Presentations at International Congress 2023
11 Sep 2023 //
GLOBENEWSWIRE
Pliant Therapeutics to Participate in Upcoming Investor Conferences
30 Aug 2023 //
GLOBENEWSWIRE
Pliant Announces Three Upcoming Presentations at the ERS Congress 2023
28 Aug 2023 //
GLOBENEWSWIRE
Pliant Therapeutics Announces Three Upcoming Presentations at the ERSIC 2023
28 Aug 2023 //
GLOBENEWSWIRE
Pliant Announces Initiation of BEACON-IPF, a Phase 2b Trial of Bexotegrast
09 Aug 2023 //
GLOBENEWSWIRE
Pliant Therapeutics Reports Second Quarter 2023 Financial Results
09 Aug 2023 //
GLOBENEWSWIRE
Pliant Therapeutics to Participate in Upcoming Investor Conferences
25 Jul 2023 //
GLOBENEWSWIRE
Pliant Therapeutics Presents Data from its Bexotegrast Program at EASL
24 Jun 2023 //
PRESS RELEASE
Pliant Therapeutics Presents Data from its Bexotegrast Program at (EASL)
23 Jun 2023 //
GLOBENEWSWIRE
Pliant Therapeutics Presents Data from its Bexotegrast Program
24 May 2023 //
GLOBENEWSWIRE
Pliant Therapeutics to Participate in Upcoming Investor Events
10 May 2023 //
GLOBENEWSWIRE
Pliant Therapeutics Provides Corporate Update and Reports1Q 2023 FYR
09 May 2023 //
GLOBENEWSWIRE
Pliant releases longer-term safety, preliminary efficacy data from PhIIa study
01 May 2023 //
ENDPTS
Pliant Therapeutics to Participate in 22nd Annual Needham Healthcare Conference
12 Apr 2023 //
GLOBENEWSWIRE
Pliant Announces Presentations at the 2023 American Thoracic Society Conference
27 Mar 2023 //
GLOBENEWSWIRE
Pliant Therapeutics begins subject enrolment in bexotegrast trial
14 Mar 2023 //
CLINICAL TRIALS ARENA

Market Place
Sourcing Support